131 related articles for article (PubMed ID: 9126929)
1. Identification of amino acid residues important for ligand binding to Fas.
Starling GC; Bajorath J; Emswiler J; Ledbetter JA; Aruffo A; Kiener PA
J Exp Med; 1997 Apr; 185(8):1487-92. PubMed ID: 9126929
[TBL] [Abstract][Full Text] [Related]
2. Analysis of the ligand binding site in Fas (CD95) by site-directed mutagenesis and comparison with TNFR and CD40.
Starling GC; Kiener PA; Aruffo A; Bajorath J
Biochemistry; 1998 Mar; 37(11):3723-6. PubMed ID: 9521690
[TBL] [Abstract][Full Text] [Related]
3. Identification of the ligand binding site in Fas (CD95) and analysis of Fas-ligand interactions.
Bajorath J
Proteins; 1999 Jun; 35(4):475-82. PubMed ID: 10382675
[TBL] [Abstract][Full Text] [Related]
4. Characterization of Fas (Apo-1, CD95)-Fas ligand interaction.
Schneider P; Bodmer JL; Holler N; Mattmann C; Scuderi P; Terskikh A; Peitsch MC; Tschopp J
J Biol Chem; 1997 Jul; 272(30):18827-33. PubMed ID: 9228058
[TBL] [Abstract][Full Text] [Related]
5. Combination of molecular mimicry and aberrant autoantigen expression is important for development of anti-Fas ligand autoantibodies in patients with systemic lupus erythematosus.
Mihara S; Suzuki N; Takeba Y; Soejima K; Yamamoto S
Clin Exp Immunol; 2002 Aug; 129(2):359-69. PubMed ID: 12165095
[TBL] [Abstract][Full Text] [Related]
6. Humanization and epitope mapping of neutralizing anti-human Fas ligand monoclonal antibodies: structural insights into Fas/Fas ligand interaction.
Nisihara T; Ushio Y; Higuchi H; Kayagaki N; Yamaguchi N; Soejima K; Matsuo S; Maeda H; Eda Y; Okumura K; Yagita H
J Immunol; 2001 Sep; 167(6):3266-75. PubMed ID: 11544314
[TBL] [Abstract][Full Text] [Related]
7. Separate domains of the human fas ligand dictate self-association and receptor binding.
Orlinick JR; Elkon KB; Chao MV
J Biol Chem; 1997 Dec; 272(51):32221-9. PubMed ID: 9405425
[TBL] [Abstract][Full Text] [Related]
8. Signal transduction. FasL binds preassembled Fas.
Golstein P
Science; 2000 Jun; 288(5475):2328-9. PubMed ID: 10917832
[TBL] [Abstract][Full Text] [Related]
9. Analysis of Fas-ligand interactions using a molecular model of the receptor-ligand interface.
Bajorath J
J Comput Aided Mol Des; 1999 Jul; 13(4):409-18. PubMed ID: 10425605
[TBL] [Abstract][Full Text] [Related]
10. Prediction of the three-dimensional structure of the human Fas receptor by comparative molecular modeling.
Bajorath J; Aruffo A
J Comput Aided Mol Des; 1997 Jan; 11(1):3-8. PubMed ID: 9139110
[TBL] [Abstract][Full Text] [Related]
11. Calmodulin binding to the Fas death domain. Regulation by Fas activation.
Ahn EY; Lim ST; Cook WJ; McDonald JM
J Biol Chem; 2004 Feb; 279(7):5661-6. PubMed ID: 14594800
[TBL] [Abstract][Full Text] [Related]
12. A non-cleavable mutant of Fas ligand does not prevent neutrophilic destruction of islet transplants.
Kang SM; Braat D; Schneider DB; O'Rourke RW; Lin Z; Ascher NL; Dichek DA; Baekkeskov S; Stock PG
Transplantation; 2000 May; 69(9):1813-7. PubMed ID: 10830216
[TBL] [Abstract][Full Text] [Related]
13. Positive and negative consequences of Fas/Fas ligand interactions in the antitumor response.
Abrams SI
Front Biosci; 2005 Jan; 10():809-21. PubMed ID: 15569621
[TBL] [Abstract][Full Text] [Related]
14. On the role and significance of Fas (Apo-1/CD95) ligand (FasL) expression in immune privileged tissues and cancer cells using multiple myeloma as a model.
Greil R; Egle A; Villunger A
Leuk Lymphoma; 1998 Nov; 31(5-6):477-90. PubMed ID: 9922038
[TBL] [Abstract][Full Text] [Related]
15. Determination of the mechanism of action of anti-FasL antibody by epitope mapping and homology modeling.
Obungu VH; Gelfanova V; Rathnachalam R; Bailey A; Sloan-Lancaster J; Huang L
Biochemistry; 2009 Aug; 48(30):7251-60. PubMed ID: 19588926
[TBL] [Abstract][Full Text] [Related]
16. In vivo inhibition of Fas ligand-mediated killing by TR6, a Fas ligand decoy receptor.
Connolly K; Cho YH; Duan R; Fikes J; Gregorio T; LaFleur DW; Okoye Z; Salcedo TW; Santiago G; Ullrich S; Wei P; Windle K; Wong E; Yao XT; Zhang YQ; Zheng G; Moore PA
J Pharmacol Exp Ther; 2001 Jul; 298(1):25-33. PubMed ID: 11408521
[TBL] [Abstract][Full Text] [Related]
17. Alpha-fetoprotein triggers hepatoma cells escaping from immune surveillance through altering the expression of Fas/FasL and tumor necrosis factor related apoptosis-inducing ligand and its receptor of lymphocytes and liver cancer cells.
Li MS; Ma QL; Chen Q; Liu XH; Li PF; Du GG; Li G
World J Gastroenterol; 2005 May; 11(17):2564-9. PubMed ID: 15849812
[TBL] [Abstract][Full Text] [Related]
18. Comparative molecular modelling of the Fas-ligand and other members of the TNF family.
Peitsch MC; Tschopp J
Mol Immunol; 1995 Jul; 32(10):761-72. PubMed ID: 7544870
[TBL] [Abstract][Full Text] [Related]
19. Fas ligand is localized to membrane rafts, where it displays increased cell death-inducing activity.
Cahuzac N; Baum W; Kirkin V; Conchonaud F; Wawrezinieck L; Marguet D; Janssen O; Zörnig M; Hueber AO
Blood; 2006 Mar; 107(6):2384-91. PubMed ID: 16282344
[TBL] [Abstract][Full Text] [Related]
20. Binding of FADD and caspase-8 to molluscum contagiosum virus MC159 v-FLIP is not sufficient for its antiapoptotic function.
Garvey TL; Bertin J; Siegel RM; Wang GH; Lenardo MJ; Cohen JI
J Virol; 2002 Jan; 76(2):697-706. PubMed ID: 11752160
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
